Last updated: 2026-10-20 02:20:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Minerva Neurosciences, Inc. (NERV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.33, with a market capitalization of $112.21M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.24 to $12.46. This page covers its latest market performance, valuation, price trends and company information.
$112.21M | |
$2.37 | |
$126.72 | |
$1.15 | |
$2.35 | |
104.78K | |
181.66K | |
-- | |
$12.46 | |
$2.24 | |
-- | |
-- |
Minerva Neurosciences, Inc. (NERV) last closed at $2.35 as of 2026-10-19 23:55:00, unchanged from the previous close of $2.35.
During the latest regular trading session, NERV traded between $1.15 and $126.72, with a volume of 104.78K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Minerva Neurosciences, Inc. (NERV) moved from $3.22 to $2.33, representing a decline of 27.67% ($0.89).
The stock traded between $2.24 and $3.37 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 157.98 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.9%
NERV is currently trading at $2.33, placing it 0.9% of the way from its 52-week low of $2.24 to its 52-week high of $12.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Minerva Neurosciences, Inc. (NERV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.